EYPT — Eyepoint Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $437.80m
- $66.89m
- $43.27m
- 33
- 18
- 15
- 10
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.3 | ||
| Price to Tang. Book | 1.3 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 10.12 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -39.48% | ||
| Return on Equity | -43.42% | ||
| Operating Margin | -337.06% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 34.44 | 36.94 | 41.4 | 46.02 | 43.27 | 24.59 | 14.16 | 16.27% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing innovative therapeutics to help improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E. DURAVYU is presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration (wet AMD). Additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The Company’s other products include YUTIQ and DEXYCU.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 20th, 2008
- Public Since
- January 27th, 2005
- No. of Shareholders
- 36
- No. of Employees
- 165
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 68,728,760
- Address
- 480 Pleasant Street, Suite C400, WATERTOWN, 02472
- Web
- https://eyepointpharma.com/
- Phone
- +1 6179265000
- Contact
- Stern
- Auditors
- Deloitte & Touche LLP
Upcoming Events for EYPT
EyePoint Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2025 EyePoint Pharmaceuticals Inc Earnings Release
Similar to EYPT
111
NASDAQ Global Market
ADMA Biologics
NASDAQ Global Market
ANI Pharmaceuticals
NASDAQ Global Market
Aquestive Therapeutics
NASDAQ Global Market
Avadel Pharmaceuticals
NASDAQ Global Market
FAQ
What is the Eyepoint Pharmaceuticals share price?
As of Today at 20:33 UTC, shares in Eyepoint Pharmaceuticals are trading at $6.37. This share price information is delayed by 15 minutes.
How has the Eyepoint Pharmaceuticals share price performed this year?
Shares in Eyepoint Pharmaceuticals last closed at $6.37 and the price had moved by -60.58% over the past 365 days. In terms of relative price strength the Eyepoint Pharmaceuticals share price has underperformed the S&P500 Index by -63.62% over the past year.
What are the analyst and broker recommendations for Eyepoint Pharmaceuticals?
The overall consensus recommendation for Eyepoint Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Eyepoint Pharmaceuticals dividend yield?
Eyepoint Pharmaceuticals does not currently pay a dividend.
Does Eyepoint Pharmaceuticals pay a dividend?
Eyepoint Pharmaceuticals does not currently pay a dividend.
When does Eyepoint Pharmaceuticals next pay dividends?
Eyepoint Pharmaceuticals does not currently pay a dividend.
How do I buy Eyepoint Pharmaceuticals shares?
To buy shares in Eyepoint Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Eyepoint Pharmaceuticals?
As of the previous close price of $6.37, shares in Eyepoint Pharmaceuticals had a market capitalisation of $437.80m.
Where are Eyepoint Pharmaceuticals shares listed?
Here are the trading details for Eyepoint Pharmaceuticals:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: EYPT
What kind of share is Eyepoint Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Eyepoint Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Eyepoint Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in Eyepoint Pharmaceuticals is $33.00. That is 418.05% above the last closing price of $6.37.
Analysts covering Eyepoint Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$2.74 for the next financial year.
Find out moreWhat is the trend in the Eyepoint Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Eyepoint Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -29.33%.
As of the last closing price of $6.37, shares in Eyepoint Pharmaceuticals were trading -21.6% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Eyepoint Pharmaceuticals PE Ratio?
The Eyepoint Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $6.37.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Eyepoint Pharmaceuticals?
We do not have data on Eyepoint Pharmaceuticals' directors